A5026262569- Blood Pressure and Hypertension Studies
- Lipoproteins and Cardiovascular Health
- Hormonal Regulation and Hypertension
- Sodium Intake and Health
- Global Public Health Policies and Epidemiology
- Cardiovascular Health and Disease Prevention
- Heart Failure Treatment and Management
- Acute Ischemic Stroke Management
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cerebrovascular and Carotid Artery Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Heart Rate Variability and Autonomic Control
- Cardiovascular Function and Risk Factors
- Cardiovascular Health and Risk Factors
- Cardiac, Anesthesia and Surgical Outcomes
- Diet and metabolism studies
- Diabetes Treatment and Management
- Renin-Angiotensin System Studies
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Nutritional Studies and Diet
- Pharmaceutical Economics and Policy
- Cardiovascular Disease and Adiposity
- Neurological Disorders and Treatments
The George Institute for Global Health
2014-2024
George Institute for Global Health
2014-2024
UNSW Sydney
1985-2024
National Health and Medical Research Council
2004-2024
Imperial College London
2013-2024
Nuffield Health
2024
Royal Marsden NHS Foundation Trust
2017-2024
Royal Marsden Hospital
2023-2024
Institute of Cancer Research
2017-2021
St George’s University Hospitals NHS Foundation Trust
2021
In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain.We randomly assigned 11,140 diabetes to undergo either standard or control, defined as use gliclazide (modified release) plus other drugs required achieve a glycated hemoglobin value 6.5% less. Primary end points were composites major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke) and microvascular (new worsening nephropathy...
In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk events, but effects on mortality from overall have remained uncertain.In double-blind, randomized trial, we compared pravastatin (40 mg daily) those placebo over mean follow-up period 6.1 years in 9014 who were 31 to 75 age. The had history myocardial infarction or hospitalization for unstable angina initial plasma total levels 155 271 per deciliter. Both groups...
Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from large study glucose lowering explore relationship between severe and adverse clinical outcomes.
<h3>Background</h3> High blood pressure and stroke are associated with increased risks of dementia cognitive impairment. This study aimed to determine whether lowering would reduce the decline among individuals cerebrovascular disease. <h3>Methods</h3> The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, double-blind, placebo-controlled trial conducted 6105 people prior or transient ischemic attack. Participants were assigned either active treatment...
There are limited data regarding whether albuminuria and reduced estimated GFR (eGFR) separate independent risk factors for cardiovascular renal events among individuals with type 2 diabetes. The Action in Diabetes Vascular disease: preterAx diamicroN-MR Controlled Evaluation (ADVANCE) study examined the effects of routine BP lowering on adverse outcomes We investigated urinary albumin-to-creatinine ratio (UACR) eGFR 10,640 patients available data. During an average 4.3-yr follow-up, 938...
AimsNiacin has potentially favourable effects on lipids, but its effect cardiovascular outcomes is uncertain. HPS2-THRIVE a large randomized trial assessing the of extended release (ER) niacin in patients at high risk vascular events.
To estimate age-, sex- and region-specific associations of blood pressure with cardiovascular diseases.Relative risk estimates 95% confidence intervals were calculated from Cox models, stratified by sex cohort, adjusted for age at on individual participant data 37 cohort studies. Repeat measurements used to adjust regression dilution bias.Studies included in the Asia Pacific Cohort Studies Collaboration Australia, mainland China, Hong Kong, Japan, New Zealand, Singapore, South Korea,...
In the Action in Diabetes and Vascular Disease: Preterax Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, combination of perindopril indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level less than 6.5%, did not. We now report results 6-year post-trial follow-up.We invited surviving participants, who had previously been assigned to perindopril-indapamide or placebo standard control...
OBJECTIVE--To examine the relation between serum cholesterol concentration and mortality (from coronary heart disease from other causes) below range of values generally seen in Western populations. DESIGN--Prospective observational study based on 8-13 years follow up subjects a population with low concentrations. SETTING--Urban Shanghai, China. SUBJECTS--9021 Chinese men women aged 35-64 at baseline. MAIN OUTCOME MEASURE--Death causes. RESULTS--The average was 4.2 mmol/l baseline...
The prevalence of white matter hyperintensities (WMHs) detected on cerebral MRI is associated with hypertension, but it not known whether blood pressure lowering can arrest their progression. We report here the results an substudy PROGRESS (Perindopril Protection Against Recurrent Stroke Study), a randomized trial in subjects cerebrovascular disease.The comprised 192 participants who had both at baseline and after mean follow-up time 36 months (SD=6.0 months). At first MRI, WMHs were graded...